<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36832180</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Dysregulated Levels of Circulating Autoantibodies against Neuronal and Nervous System Autoantigens in COVID-19 Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">687</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics13040687</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 is a heterogenous disease resulting in long-term sequela in predisposed individuals. It is not uncommon that recovering patients endure non-respiratory ill-defined manifestations, including anosmia, and neurological and cognitive deficit persisting beyond recovery-a constellation of conditions that are grouped under the umbrella of long-term COVID-19 syndrome. Association between COVID-19 and autoimmune responses in predisposed individuals was shown in several studies.</AbstractText><AbstractText Label="AIM AND METHODS" NlmCategory="OBJECTIVE">To investigate autoimmune responses against neuronal and CNS autoantigens in SARS-CoV-2-infected patients, we performed a cross-sectional study with 246 participants, including 169 COVID-19 patients and 77 controls. Levels of antibodies against the acetylcholine receptor, glutamate receptor, amyloid &#x3b2; peptide, alpha-synucleins, dopamine 1 receptor, dopamine 2 receptor, tau protein, GAD-65, N-methyl D-aspartate (NMDA) receptor, BDNF, cerebellar, ganglioside, myelin basic protein, myelin oligodendrocyte glycoprotein, S100-B, glial fibrillary acidic protein, and enteric nerve were measured using an Enzyme-Linked Immunosorbent Assay (ELISA). Circulating levels of autoantibodies were compared between healthy controls and COVID-19 patients and then classified by disease severity (mild [<i>n</i> = 74], severe [<i>n</i> = 65], and requiring supplemental oxygen [<i>n</i> = 32]).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19 patients were found to have dysregulated autoantibody levels correlating with the disease severity, e.g., IgG to dopamine 1 receptor, NMDA receptors, brain-derived neurotrophic factor, and myelin oligodendrocyte glycoprotein. Elevated levels of IgA autoantibodies against amyloid &#x3b2; peptide, acetylcholine receptor, dopamine 2 receptor, myelin basic protein, and &#x3b1;-synuclein were detected in COVID-19 patients compared with healthy controls. Lower IgA autoantibody levels against NMDA receptors, and IgG autoantibodies against glutamic acid decarboxylase 65, amyloid &#x3b2; peptide, tau protein, enteric nerve, and S100-B were detected in COVID-19 patients versus healthy controls. Some of these antibodies have known clinical correlations with symptoms commonly reported in the long COVID-19 syndrome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, our study shows a widespread dysregulation in the titer of various autoantibodies against neuronal and CNS-related autoantigens in convalescent COVID-19 patients. Further research is needed to provide insight into the association between these neuronal autoantibodies and the enigmatic neurological and psychological symptoms reported in COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lavi</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3162-0988</Identifier><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vojdani</LastName><ForeName>Aristo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2925-9334</Identifier><AffiliationInfo><Affiliation>Immunosciences Lab, Inc., Los Angeles, CA 90035, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cyrex Laboratories, LLC, Phoenix, AZ 85034, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halpert</LastName><ForeName>Gilad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Ariel University, Ariel 40700, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Kassem</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrinski</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zyskind</LastName><ForeName>Israel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-3422-9631</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, NYU Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Medical Center, Brooklyn, NY 11219, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lattin</LastName><ForeName>Miriam T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Biology, Yeshiva University, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7372-1376</Identifier><AffiliationInfo><Affiliation>Maimonides Medical Center, Brooklyn, NY 11219, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverberg</LastName><ForeName>Jonathan I</ForeName><Initials>JI</Initials><Identifier Source="ORCID">0000-0003-3686-7805</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Avi Z</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoenfeld</LastName><ForeName>Yehuda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amital</LastName><ForeName>Howard</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5406-7716</Identifier><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>0000</GrantID><Agency>Yaron and Gila Shemie Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoantigens</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">central nervous system</Keyword></KeywordList><CoiStatement>Aristo Vojdani is the co-owner, CEO and technical director of Immunosciences Lab., Inc. in Los Angeles, CA. He is the Chief Scientific Advisor in a consultancy position for Cyrex Labs, LLC in Phoenix, AZ. The rest of authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>1</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36832180</ArticleId><ArticleId IdType="pmc">PMC9955917</ArticleId><ArticleId IdType="doi">10.3390/diagnostics13040687</ArticleId><ArticleId IdType="pii">diagnostics13040687</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Halpert G., Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun. Rev. 2020;19:102695. doi: 10.1016/j.autrev.2020.102695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102695</ArticleId><ArticleId IdType="pmc">PMC7598743</ArticleId><ArticleId IdType="pubmed">33130000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M. COVID-19 and autoimmunity. Autoimmun. Rev. 2020;19:102597. doi: 10.1016/j.autrev.2020.102597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102597</ArticleId><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Zuniga M., A Crotty K., Qian K., Tovar N.C., Lin L.H., Argyropoulos K.V., Clancy R., Izmirly P., Buyon J., et al. Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. Life Sci. Alliance. 2021;4:e202101180. doi: 10.26508/lsa.202101180.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202101180</ArticleId><ArticleId IdType="pmc">PMC8441539</ArticleId><ArticleId IdType="pubmed">34504035</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers M.S., Rosen L.B., Delmonte O.M., Shaw E., Bastard P., Imberti L., Quaresima V., Biondi A., Bonfanti P., Castagnoli R., et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol. Cell Biol. 2021;99:917&#x2013;921. doi: 10.1111/imcb.12495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12495</ArticleId><ArticleId IdType="pmc">PMC8444766</ArticleId><ArticleId IdType="pubmed">34309902</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Rosenberg A.Z., Shoenfeld Y. The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens. Pathophysiology. 2022;29:243&#x2013;280. doi: 10.3390/pathophysiology29020020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathophysiology29020020</ArticleId><ArticleId IdType="pmc">PMC9231084</ArticleId><ArticleId IdType="pubmed">35736648</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L., Motta F., De Santis M., Ansari A.A., Gershwin M.E., Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19&#x2014;A systematic review of the literature. J. Autoimmun. 2020;117:102592. doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancheva L., Petralia M.C., Miteva S., Dragomanova S., Solak A., Kalfin R., Lazarova M., Yarkov D., Ciurleo R., Cavalli E., et al. Emerging Neurological and Psychobiological Aspects of COVID-19 Infection. Brain Sci. 2020;10:852. doi: 10.3390/brainsci10110852.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10110852</ArticleId><ArticleId IdType="pmc">PMC7696269</ArticleId><ArticleId IdType="pubmed">33198412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K., F&#xfc;rst J., Schulze-Rothe S., Wallukat A., H&#xf6;nicke A.-S., M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins with Tissue Antigens: Implications for Autoimmune Diseases. Front. Immunol. 2020;11:617089. doi: 10.3389/fimmu.2020.617089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.617089</ArticleId><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 2020;217:108480. doi: 10.1016/j.clim.2020.108480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108480</ArticleId><ArticleId IdType="pmc">PMC7246018</ArticleId><ArticleId IdType="pubmed">32461193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E. Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42. Int. J. Alzheimer&#x2019;s Dis. 2018;2018:1672568. doi: 10.1155/2018/1672568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1672568</ArticleId><ArticleId IdType="pmc">PMC6032666</ArticleId><ArticleId IdType="pubmed">30034864</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Saidara E., Kharrazian D. Reaction of Amyloid-&#x3b2; Peptide Antibody with Different Infectious Agents Involved in Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2018;63:847&#x2013;860. doi: 10.3233/JAD-170961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170961</ArticleId><ArticleId IdType="pubmed">29689721</ArticleId></ArticleIdList></Reference><Reference><Citation>Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 2005;12:392&#x2013;398. doi: 10.1111/j.1468-1331.2004.00976.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2004.00976.x</ArticleId><ArticleId IdType="pubmed">15804272</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y., Ryabkova V.A., Scheibenbogen C., Brinth L., Martinez-Lavin M., Ikeda S., Heidecke H., Watad A., Bragazzi N.L., Chapman J., et al. Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. Clin. Immunol. 2020;214:108384. doi: 10.1016/j.clim.2020.108384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108384</ArticleId><ArticleId IdType="pubmed">32171889</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackburn K.M., Wang C. Post-infectious neurological disorders. Ther. Adv. Neurol. Disord. 2020;13:1756286420952901. doi: 10.1177/1756286420952901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286420952901</ArticleId><ArticleId IdType="pmc">PMC7466892</ArticleId><ArticleId IdType="pubmed">32944082</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O., Halpert G., Schimke L.F., Ostrinski Y., Vojdani A., Baiocchi G.C., Freire P.P., Filgueiras I.S., Zyskind I., Lattin M.T., et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat. Commun. 2022;13:1220. doi: 10.1038/s41467-022-28905-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28905-5</ArticleId><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason B.L., Lobo M.K., Parada L.F., Lutter M. Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight. Obesity. 2013;21:2372&#x2013;2376. doi: 10.1002/oby.20382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.20382</ArticleId><ArticleId IdType="pmc">PMC3742719</ArticleId><ArticleId IdType="pubmed">23512795</ArticleId></ArticleIdList></Reference><Reference><Citation>Girgis R.R., Van Snellenberg J.X., Glass A., Kegeles L.S., Thompson J.L., Wall M., Cho R.Y., Carter C.S., Slifstein M., Abi-Dargham A., et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J. Psychopharmacol. 2016;30:428&#x2013;435. doi: 10.1177/0269881116636120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881116636120</ArticleId><ArticleId IdType="pubmed">26966119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagena H., Manahan-Vaughan D. Dopamine D1/D5, But not D2/D3, Receptor Dependency of Synaptic Plasticity at Hippocampal Mossy Fiber Synapses that Is Enabled by Patterned Afferent Stimulation, or Spatial Learning. Front. Synaptic Neurosci. 2016;8:31. doi: 10.3389/fnsyn.2016.00031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnsyn.2016.00031</ArticleId><ArticleId IdType="pmc">PMC5033958</ArticleId><ArticleId IdType="pubmed">27721791</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Tsien J.Z. Memory and the NMDA Receptors. N. Engl. J. Med. 2009;361:302&#x2013;303. doi: 10.1056/NEJMcibr0902052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr0902052</ArticleId><ArticleId IdType="pmc">PMC3703758</ArticleId><ArticleId IdType="pubmed">19605837</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevska V., Guest P.C., Bernstein H.-G., Schroeter M.L., Geis C., Steiner J. Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases. J. Neuroinflammation. 2021;18:245. doi: 10.1186/s12974-021-02293-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02293-x</ArticleId><ArticleId IdType="pmc">PMC8551937</ArticleId><ArticleId IdType="pubmed">34711233</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekinschtein P., Cammarota M., Katche C., Slipczuk L., Rossato J.I., Goldin A., Izquierdo I., Medina J.H. BDNF is essential to promote persistence of long-term memory storage. Proc. Natl. Acad. Sci. USA. 2008;105:2711&#x2013;2716. doi: 10.1073/pnas.0711863105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711863105</ArticleId><ArticleId IdType="pmc">PMC2268201</ArticleId><ArticleId IdType="pubmed">18263738</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda M., Morici J.F., Zanoni M.B., Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front. Cell. Neurosci. 2019;13:363. doi: 10.3389/fncel.2019.00363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00363</ArticleId><ArticleId IdType="pmc">PMC6692714</ArticleId><ArticleId IdType="pubmed">31440144</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes B.S., Molendijk M.L., K&#xf6;hler C.A., Soares J.C., Leite C.M.G.S., Machado-Vieira R., Ribeiro T.L., Silva J.C., Sales P.M.G., Quevedo J., et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: A meta-analysis of 52 studies. BMC Med. 2015;13:289. doi: 10.1186/s12916-015-0529-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0529-7</ArticleId><ArticleId IdType="pmc">PMC4666054</ArticleId><ArticleId IdType="pubmed">26621529</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschl P., Bradl M., H&#xf6;ftberger R., Berger T., Reindl M. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front. Immunol. 2017;8:529. doi: 10.3389/fimmu.2017.00529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00529</ArticleId><ArticleId IdType="pmc">PMC5420591</ArticleId><ArticleId IdType="pubmed">28533781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouali-Benazzouz R., Benazzouz A. COVID-19 Infection and Parkinsonism: Is There a Link? Mov. Disord. 2021;36:1737&#x2013;1743. doi: 10.1002/mds.28680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28680</ArticleId><ArticleId IdType="pmc">PMC8242862</ArticleId><ArticleId IdType="pubmed">34080714</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal-Carvallo J.F., Jankovic J. Autoimmune and paraneoplastic movement disorders: An update. J. Neurol. Sci. 2018;385:175&#x2013;184. doi: 10.1016/j.jns.2017.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.12.035</ArticleId><ArticleId IdType="pubmed">29406902</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinas J.E., Matveychuk D., Dursun S.M., Baker G.B. Neuroimmunological antibody-mediated encephalitis and implications for diagnosis and therapy in neuropsychiatry. Acta Neuropsychiatr. 2019;32:177&#x2013;185. doi: 10.1017/neu.2019.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/neu.2019.50</ArticleId><ArticleId IdType="pubmed">31791436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Beumer J., Van Der Vaart J., Knoops K., Puschhof J., Breugem T.I., Ravelli R.B., Paul van Schayck J., Mykytyn A.Z., Duimel H.Q., et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369:50&#x2013;54. doi: 10.1126/science.abc1669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Turnpaugh C.C. Antibodies against Group A Streptococcus, dopamine receptors, and ganglioside GM1 cross-react with a variety of food antigens, potentially interfering with biomarkers for PANS and PANDAS. Biomark. Neuropsychiatry. 2020;3:100023. doi: 10.1016/j.bionps.2020.100023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bionps.2020.100023</ArticleId></ArticleIdList></Reference><Reference><Citation>Maftei M., Thurm F., Schnack C., Tumani H., Otto M., Elbert T., Kolassa I.-T., Przybylski M., Manea M., Von Arnim C.A.F. Increased Levels of Antigen-Bound &#x3b2;-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer&#x2019;s Disease Patients. PLoS ONE. 2013;8:e68996. doi: 10.1371/journal.pone.0068996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068996</ArticleId><ArticleId IdType="pmc">PMC3715516</ArticleId><ArticleId IdType="pubmed">23874844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartos A., Fialov&#xe1; L., &#x160;varcov&#xe1; J. Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2018;64:751&#x2013;760. doi: 10.3233/JAD-180039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180039</ArticleId><ArticleId IdType="pubmed">29966192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zyskind I., Rosenberg A.Z., Zimmerman J., Naiditch H., Glatt A.E., Pinter A., Theel E.S., Joyner M.J., Hill D.A., Lieberman M.R., et al. SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States. JAMA Netw. Open. 2021;4:e212816. doi: 10.1001/jamanetworkopen.2021.2816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.2816</ArticleId><ArticleId IdType="pmc">PMC7948060</ArticleId><ArticleId IdType="pubmed">33688968</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>